The protein APLP1 strongly associates with brain-derived EVs. A blood test could one day isolate these molecular packets to diagnose neurological disorders.
A new technique boosts the sensitivity of mass cytometry to allow detection and characterization of low-abundance markers, yielding new disease insights.
By activating CAR T cells only in the presence of an antibody switch, Travis Young and his team hope to make this cancer treatment safer and more effective.